Go Pro
NYSEAMERICAN:CVRS

Corindus Vascular Robotics (CVRS) Stock Price, News & Analysis

Corindus Vascular Robotics logo
$4.27 0.00 (0.00%)
As of 11/27/2019

About Corindus Vascular Robotics Stock (NYSEAMERICAN:CVRS)

Key Stats

Today's Range
$4.27
$4.27
50-Day Range
$4.27
$4.27
52-Week Range
$0.78
$4.40
Volume
N/A
Average Volume
1.99 million shs
Market Capitalization
$891.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Corindus Vascular Robotics develops and manufactures robotic-assisted systems designed to enhance the precision and safety of catheter-based vascular interventions. Its solutions enable interventional cardiologists and radiologists to remotely manipulate guidewires, balloons, stents and other devices during percutaneous procedures, while reducing radiation exposure and physical strain on clinical staff. By integrating robotics with imaging and control software, the company aims to improve procedural consistency and patient outcomes in complex vascular treatments.

The company’s flagship offering, the CorPath System, has received regulatory clearances for a range of applications in both coronary and peripheral vascular interventions. The platform features a single-use disposable cassette and an operator console that can be positioned several feet from the patient table, allowing clinicians to carry out precise device movements with sub-millimeter accuracy. Subsequent iterations, such as the CorPath GRX System, have introduced expanded compatibility with interventional devices and software enhancements designed to streamline procedure workflows.

Founded in 2002 and headquartered in Waltham, Massachusetts, Corindus Vascular Robotics established itself as a pioneer in vascular robotics and completed its initial public offering on the NYSE American under the ticker CVRS. In 2019, the company was acquired by Siemens Healthineers, becoming part of its broader portfolio of minimally invasive treatment solutions. This integration has enabled Corindus to leverage Siemens’ global infrastructure, R&D resources and clinical network to accelerate the adoption of robotic-assisted interventions.

Corindus serves hospitals and catheterization laboratories across North America, Europe, Asia Pacific and select emerging markets. As a business unit within Siemens Healthineers, its management and development efforts are aligned with the parent company’s commitment to driving innovation in image-guided therapies. The continued rollout of robotic platforms underscores the company’s strategic focus on transforming interventional procedures through automation and digital connectivity.

AI Generated. May Contain Errors.

Receive CVRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corindus Vascular Robotics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

CVRS Stock News Headlines

Corindus Vascular Robotics, Inc.
HealthCor Partners Fund II, L.P.'s Net Worth
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.tc pixel
Robotics & AI
See More Headlines

CVRS Stock Analysis - Frequently Asked Questions

Corindus Vascular Robotics' stock was trading at $4.27 at the start of the year. Since then, CVRS stock has increased by 0.0% and is now trading at $4.27.

Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) released its quarterly earnings data on Tuesday, August, 7th. The medical equipment provider reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.01. The medical equipment provider earned $1.67 million during the quarter, compared to analysts' expectations of $3 million.

Shares of CVRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Corindus Vascular Robotics investors own include Amarin (AMRN), TransEnterix (TRXDW), Micron Technology (MU), Advanced Micro Devices (AMD), NVIDIA (NVDA), Helios and Matheson Analytics (HMNY) and Meta Platforms (META).

Company Calendar

Last Earnings
8/07/2018
Today
8/15/2026

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Healthcare Equipment & Supplies
Sub-Industry
Healthcare Equipment
Current Symbol
NYSEAMERICAN:CVRS
Previous Symbol
NYSEMKT:CVRS
CIK
N/A
Fax
N/A
Employees
90
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
208,685,000
Free Float
N/A
Market Cap
$891.08 million
Optionable
Not Optionable
Beta
N/A
7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NYSEAMERICAN:CVRS) was last updated on 8/15/2026 by MarketBeat.com Staff.
From Our Partners